QUOTED. 14 October 2020. Gerard von Hoffmann.
Companies entering clinical trials may be in the worst position to ride out COVID-19, says Gerard von Hoffmann, partner, Knobbe Martens. Here’s why he isn’t sure taking trials overseas is a solution.
“I have seen a couple of companies just step up their efforts to find a jurisdiction outside of the United States to conduct trials on technologies that they did not feel would be considered essential services, at least for some period of time. But the problem is it takes so long and the regulatory effort is so extreme, I'm not sure there's a lot of shortcuts.” – Gerard von Hoffman, partner, Knobbe MartensClick here for a free trial of Medtech Insight